Skip to content

Press Releases and Events

PRESS RELEASES AND EVENTS

Events

There are currently no events to display.

Archived Events

There are currently no events to display.

Press Releases

Date Title and Summary View
Toggle Summary Intra-Cellular Therapies Announces Upcoming Presentations at the 4th Biennial Schizophrenia International Research Society Conference View HTML
Toggle Summary Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2013 Financial Results
– Conference Call and Webcast Today, March 25, at 4:30 p.m. ET –
View HTML
Toggle Summary Intra-Cellular Therapies to Announce 2013 Fourth Quarter And Full Year Financial Results and to Host Conference Call on Tuesday, March 25, at 4:30 pm Eastern Time View HTML
Toggle Summary Intra-Cellular Therapies Announces the Appointment of Juan Sanchez, M.D., as Vice President of Corporate Communications and Investor Relations View HTML
Toggle Summary Intra-Cellular Therapies Announces Initiation of Phase I/II Clinical Trial for ITI-007 in Healthy Geriatric Subjects and Patients with Dementia, Including Alzheimer's Disease View HTML
Toggle Summary Intra-Cellular Therapies to Present at the Cowen and Company 34th Annual Healthcare Conference View HTML
Toggle Summary Intra-Cellular Therapies to Present at Two Upcoming Healthcare Conferences View HTML
Toggle Summary Intra-Cellular Therapies Announces Completion of Public Offering and Exercise of Option to Purchase Additional Shares. View HTML
Toggle Summary Intra-Cellular Therapies Announces Pricing of Public Offering of Common Stock; To Begin Trading on NASDAQ Global Select Market under "ITCI" View HTML
Toggle Summary Intra-Cellular Therapies Cleared for Quotation on OTCQB.
Intra-Cellular Therapies, Inc. ("ITI"), a biopharmaceutical company focused on the development of therapeutics for CNS disorders, announced that its common stock has been approved for quotation on the OTC Markets - OTCQB tier (OTCQB) under the symbol "ITCI", and is expected to begin trading on December 20, 2013.
View HTML
Toggle Summary Intra-Cellular Therapies Announces Positive Topline Phase II Clinical Results of ITI-007 for the Treatment of Schizophrenia
- Company to Host Conference Call on Monday, December 9, at 10:00 am Eastern Time to Discuss Trial Results -
View HTML
Toggle Summary Intra-Cellular Therapies announces closing of $60 Million Private Placement and Completion of Reverse Merger. View HTML
Toggle Summary Intra-Cellular Therapies Appoints Professor Sir Michael Rawlins to its Board of Director. View HTML
Toggle Summary Intra-Cellular Therapies Announces Completion of Phase I Single Rising Dose Trial of First-In-Class Selective Phosphodiesterase 1 (PDE1) Inhibitor and Reports Top-Line Safety and Pharmacokinetic Findings.
Intra-Cellular Therapies, Inc. ("ITI") today announced the completion of a Phase I single rising dose study of its phosphodiesterase 1 (PDE1) inhibitor, ITI-214. ITI-214, a novel, first-in-class selective PDE1 inhibitor, was discovered by ITI and is in development under an exclusive collaboration with Takeda Pharmaceutical Company Limited for the treatment of Cognitive Impairment Associated with Schizophrenia (CIAS).
View HTML
Toggle Summary Intra-Cellular Therapies and Takeda enter into Worldwide Collaboration to Develop and Commercialize Compounds for Schizophrenia
Intra-Cellular Therapies, Inc. ("ITI") and Takeda Pharmaceutical Company Limited (TSE: 4502, "Takeda"), today announced that they have entered into an exclusive collaboration to develop and commercialize selective phosphodiesterase type 1 (PDE1) inhibitors, discovered by ITI, for the treatment of cognitive impairment associated with schizophrenia. This agreement is targeted worldwide, but ITI has retained the option to co-promote with Takeda in the United States. ITI's PDE1 inhibitors are unique, orally available, preclinical stage compounds. These compounds have potential to be treatments for a variety of psychiatric and neurological diseases.
View HTML